Anbio Biotechnology NNNN PHARMA
Company Overview
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.
Why Investors Should Care
Generates a return on equity of 27.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 19.1%.
Maintains a net profit margin of 74.1%.
Recent Developments
- Dec 2025 Revenue of $8.65M (+5.6% YoY); net profit $6.40M.
- Trailing 12 Months Year-on-year growth — revenue +73.9%, earnings +169.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -28.4%, profit CAGR -13.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -28.39% |
| 1 Year: | 73.90% |
Compounded Profit Growth
| 5 Years: | -13.84% |
| 1 Year: | 169.86% |
Stock Price Performance
| 1 Year: | -86.66% |
| 6 Months: | -70.82% |
| 3 Months: | -62.37% |
| 1 Month: | -38.93% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)29.27 · Oversold
P/E of 43.20 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 27.0%.
- Excellent profit margin of 74.1%.
CONS
- Revenue declined at -28.4% CAGR over 5 years.
- Earnings shrank at -13.8% CAGR over 5 years.
- Trading 87.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NNNN Anbio Biotechnology PHARMA | 6.48 | 43.20 | $284.41M | 0.00% | 19.13% | 27.05% | -28.39% | -13.84% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 23.54M | 6.71M | 8.19M | 8.65M |
| Cost of Revenue | - | 10.98M | 3.35M | 2.30M | 1.10M |
| Gross Profit | - | 12.56M | 3.36M | 5.89M | 7.54M |
| Operating Expenses | - | 2.37M | 1.40M | 3.89M | 1.78M |
| Operating Income | - | 10.20M | 1.96M | 2.00M | 5.77M |
| EBITDA | - | 10.03M | 1.97M | 2.00M | 5.77M |
| Interest Expense | 0 | 8.00K | 0 | 0 | - |
| Pretax Income | - | 10.01M | 2.25M | 2.37M | 6.40M |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Net Income | - | 10.01M | 2.25M | 2.37M | 6.40M |
| Diluted EPS | 0.03 | 0.07 | 0.01 | 0.05 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 13.96M | 15.81M | 18.92M | 30.24M |
| Current Assets | - | 13.94M | 15.75M | 18.53M | 30.24M |
| Cash & Equivalents | - | 7.10M | 9.69M | 11.76M | 7.77M |
| Inventory | 0 | 353.87K | 0 | - | - |
| Receivables | - | 0 | 1.88M | 1.06M | 3.66M |
| Total Liabilities | - | 1.41M | 993.06K | 1.73M | 87.84K |
| Current Liabilities | - | 1.41M | 993.06K | 1.73M | 87.84K |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
| Total Equity | - | 12.55M | 14.82M | 17.19M | 30.16M |
| Shares Outstanding | - | 43.89M | 43.89M | 43.89M | 43.89M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 4.45M | 898.37K | 2.08M | -6.74M |
| Investing Cash Flow | - | -1.53M | 1.73M | 337.10K | -4.20M |
| Financing Cash Flow | - | 0 | -42.84K | -344.61K | 6.95M |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | 4.45M | 898.37K | 2.08M | -6.74M |
| Net Change in Cash | - | 2.92M | 2.59M | 2.07M | -3.99M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 53.4% | 50.1% | 71.9% | 87.2% |
| Operating Margin % | - | 43.3% | 29.2% | 24.4% | 66.7% |
| Net Margin % | - | 42.5% | 33.6% | 29.0% | 74.1% |
| ROE % | - | 79.8% | 15.2% | 13.8% | 21.2% |
| ROCE % | - | 81.3% | 13.2% | 11.6% | 19.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 0.06% | 26.74K | $140.36K |
| 2 | BNP Paribas Financial Markets | 0.03% | 11.80K | $61.95K |
| 3 | Marshall Wace LLP | 0.03% | 11.50K | $60.38K |
| 4 | Bank of America Corporation | 0.03% | 13.42K | $70.45K |
| 5 | Morgan Stanley | 0.02% | 7.23K | $37.96K |
| 6 | Eversource Wealth Advisors, Llc | - | 187 | $981 |
| 7 | Bare Financial Services, Inc | - | 15 | $78 |
| 8 | JPMORGAN CHASE & CO | - | 53 | $278 |
| 9 | UBS Group AG | - | 828 | $4.35K |
| 10 | Osaic Holdings Inc. | - | 77 | $404 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NNNN
Undiscovered Gems US Market April 2026
The United States market has experienced a flat performance over the last week, yet it has seen an impressive 30% rise over the past year with earnings projected to grow by 16% annually. In this dynamic environment, identifying stocks that …
Discover 3 Undiscovered Gems in the US Market
The United States market has experienced a notable rise, climbing 1.8% in the last week and up 28% over the past year, with earnings projected to grow by 17% annually. In such a robust environment, identifying stocks that combine strong fun…
Uncovering US Market's 3 Undiscovered Gems With Potential
The United States market has experienced a notable rise, with a 1.3% increase over the last week and a substantial 28% gain in the past year, while earnings are projected to grow by 17% annually in the coming years. In such an environment, …
Discovering US Undiscovered Gems In May 2026
Over the last 7 days, the United States market has experienced a slight dip of 1.0%, yet it has shown impressive growth of 23% over the past year, with earnings anticipated to increase by 17% annually in the coming years. In such dynamic co…
Discovering Hidden Opportunities in US Stocks with Strong Potential
The United States market has shown robust performance, rising 1.1% over the last week and 27% over the past year, with earnings projected to grow by 17% annually. In this thriving environment, a good stock often combines strong fundamentals…
Undiscovered Gems in the US Market for May 2026
The United States market has recently experienced a robust performance, climbing 3.2% in the last week and showing an impressive 31% increase over the past year. In such a dynamic environment, identifying stocks with strong growth potential…
NNNN — Frequently Asked Questions
What is the current share price of Anbio Biotechnology (NNNN)?
As of 2026-09-19 21:16 PDT, Anbio Biotechnology (NNNN) trades at $6.48 on NasdaqGM. Its 52-week range is $6.48 to $52.10.
What is the market capitalisation of NNNN?
Anbio Biotechnology (NNNN) has a market capitalisation of $284.41M on NasdaqGM.
What is the P/E ratio of NNNN?
NNNN trades at a trailing price-to-earnings (P/E) ratio of 43.20. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 7.64.
What is the return on equity (ROE) of NNNN?
NNNN has a return on equity (ROE) of 27.05%. Its return on capital employed (ROCE) is 19.13%.
Is NNNN a good stock to buy?
This page provides a data-driven analysis of Anbio Biotechnology (NNNN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.